Medico Remedies Reports Negative Financial Results for Q2 FY25

Nov 18 2024 12:53 PM IST
share
Share Via
Medico Remedies, a microcap pharmaceutical company, has reported a negative performance in the second quarter of fiscal year 2024-2025. The company's score has fallen from 4 to -6, with a decrease in operating cash flow and net sales. MarketsMojo has given a 'Sell' call for the company's stock based on these results.

Medico Remedies, a microcap pharmaceutical company, has recently announced its financial results for the quarter ending September 2024. According to the report released on November 12, 2024, the company has seen a negative performance in the second quarter of the fiscal year 2024-2025.


The company’s score has fallen from 4 to -6 in the last three months, indicating a decline in its financial health. This can be attributed to various factors, including a decrease in operating cash flow, which has been the lowest in the last three years at Rs 2.68 crore. This suggests that the company’s cash revenues from business operations are declining.


Furthermore, the net sales for the quarter have also shown a negative trend, with a growth rate of -7.11% year on year at Rs 39.35 crore. This indicates a decline in the company’s sales performance in the near term. The operating profit (PBDIT) for the quarter has also been the lowest in the last five quarters at Rs 2.42 crore, further highlighting the negative trend in the company’s financials.


The operating profit margin for the quarter has also been the lowest in the last five quarters at 6.15%, indicating a deterioration in the company’s efficiency. Additionally, the profit before tax less other income (PBT) for the quarter has been the lowest in the last five quarters at Rs 1.45 crore, further reflecting the negative trend in the company’s financial performance.


Based on these financial results, MarketsMOJO has given a ‘Sell’ call for Medico Remedies’ stock. It is important for investors to carefully consider these financials before making any investment decisions.


{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News